Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Repros Therapeutics (RPRX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 48,510
  • Shares Outstanding, K 24,320
  • Annual Sales, $ 10 K
  • Annual Income, $ -29,190 K
  • 36-Month Beta -0.78
  • Price/Sales 4,410.36
  • Price/Book 5.56

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +8.00%
on 11/09/16
2.15 -24.65%
on 11/15/16
unch (unch)
since 11/07/16
3-Month
1.50 +8.00%
on 11/09/16
2.47 -34.41%
on 09/08/16
-0.28 (-14.74%)
since 09/07/16
52-Week
0.80 +102.50%
on 02/24/16
3.48 -53.45%
on 04/14/16
+0.20 (+14.08%)
since 12/07/15

Most Recent Stories

More News
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Repros Therapeutics Inc.(R) (Nasdaq:RPRX) participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting today. The panel provided the FDA with advice...

Repros (RPRX) Reports Positive Top-Line Data on Proellex

Repros Therapeutics Inc. (RPRX) reported top-line results from two phase II studies on its lead pipeline candidate, Proellex, when delivered orally and vaginally for the treatment of uterine fibroids.

Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus

Repros Therapeutics Inc. (RPRX) reported a loss of 17 cents per share in the third quarter of 2016, significantly narrower than the year-ago loss of 27 cents.

Repros Therapeutics Inc.(R) Reports Third Quarter 2016 Financial Results

Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2016.

What to Expect from Repros (RPRX) This Earnings Season

Repros Therapeutics Inc. (RPRX) is expected to report third-quarter 2016 results on Nov 14.

What to Expect from Repros (RPRX) This Earnings Season

What to Expect from Repros (RPRX) This Earnings Season

What to Expect from Repros (RPRX) This Earnings Season

What to Expect from Repros (RPRX) This Earnings Season

Repros' Secondary Hypogonadism Drug under Review in EU

Repros Therapeutics' (RPRX) regulatory application for enclomiphene has been accepted for review in the EU.

Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced that it has received confirmation of acceptance of its September 12, 2016 filing for enclomiphene in the treatment of secondary hypogonadism in...

FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

-- Repros Therapeutics to participate as a Sponsor -- developing a therapy specifically designed to treat secondary hypogonadism

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer. Zonagen's products to treat...

See More

Support & Resistance

2nd Resistance Point 1.83
1st Resistance Point 1.73
Last Price 1.62
1st Support Level 1.57
2nd Support Level 1.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.